Leading Pharmaceutical Companies Mid-day Trading with Mixed Results and also New Patent News Announced for Crown Marketing
CORAL SPRINGS, Florida, February 14, 2013 /PRNewswire/ --
FinancialNewsMedia.com reports on active HealthCare Companies experiencing mid-day trading today with mixed results: Crown Marketing Pharmaceutical, Abbott Laboratories (NYSE: ABT), Bristol-Myers Squibb Company (NYSE: BMY), GNC Holdings, Inc. (NYSE: GNC) and Pfizer Inc. (NYSE: PFE).
Crown Marketing Pharmaceuticals was trading higher than normal volume by mid-day trading over 1.5 Million Shares as the company issued news before the markets opened today. To read the entire following press release details along with all the recent Crown news, please go to http://www.marketwatch.com/investing/stock/cwnm. The press release states Crown Marketing announced today that Patents for its Controlled Drug Delivery Technology (CDDT) have been approved and registered in South Africa. This is the Company's second major announcement regarding the approval of new Patents following last week's news it had also secured Patents in Norway. Crown is continuing to secure its worldwide patent rights as it pursues novel applications of its drug delivery technology. For more details regarding Crown's CDDT applications, go to http://crowncddt.com/technology/
Abbott Laboratories (NYSE: ABT) engages in the discovery, development, manufacture, and sale of health care products worldwide. It offers diagnostic systems and tests, such as immunoassay and clinical chemistry systems; assays for screening and/or diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, and physiological and infectious diseases. ABT was up $0.14 per share at mid-day trading on 4.5 Million shares by 12:30pm EST.
Bristol-Myers Squibb Company (NYSE: BMY) announced this week it has entered into a three-year collaboration agreement with Reckitt Benckiser Group plc (LSE: RBL) for several of its over-the-counter medicines currently sold across Latin America, primarily in Mexico and Brazil. BMY was up slightly in mid-day trading at $36.40 per share on 4.1 Million shares by 12:30pm EST.
GNC Holdings, Inc. (NYSE: GNC), a leading global specialty retailer of health and wellness products, today reported its financial results for the quarter and year ended December 31, 2012. Get the full report at http://www.marketwatch.com/investing/stock/gnc. GNC was up over 8% in mid-day trading at $39.14 per share on 6.7 Million shares by 12:45pm EST.
Pfizer Inc. (NYSE: PFE), a biopharmaceutical company, engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide. It primarily offers Celebrex, Chantix/Champix, Lipitor, Lyrica, Premarin, Pristiq, and Viagra pharmaceutical products in the therapeutic and disease areas of Alzheimer’s disease, cardiovascular, erectile dysfunction, genitourinary, depressive disorder, pain, respiratory, and smoking cessation. GNC was up slightly in mid-day trading at $27.07 per share on 14.7 Million shares by 12:55pm EST.
FinancialNewsMedia.com is a leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.
FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
SOURCE FN Media Group LLC
More by this Source
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.